HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the second quarter ended June 30, 2011. “We are encouraged by the positive prescriber response to programs we initiated in the second quarter. These programs highlight AMPYRA’s efficacy across a wide range of walking disability, from mild to severe, in people with MS,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “Our market research shows that an increasing number of physicians intend to prescribe AMPYRA in relapsing remitting MS patients, who typically have less severe walking impairment than progressive patients.”
